Virtus ETF Advisers’s Stemline Therapeutics, Inc. STML Stock Holding History

Virtus ETF Advisers’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-58,544	Closed	-$283K	–	496
2020 Q1	$283K	Sell	58,544 -4,940	-8%	-$32K	0.12%	233
2019 Q4	$675K	Buy	63,484 +14,578	+30%	+$145K	0.11%	158
2019 Q3	$509K	Sell	48,906 -8,221	-14%	-$108K	0.1%	180
2019 Q2	$875K	Buy	57,127 +30,273	+113%	+$438K	0.18%	161
2019 Q1	$345K	Sell	26,854 -2,869	-10%	-$32.4K	0.73%	47
2018 Q4	$282K	Buy	29,723 +2,982	+11%	+$38.7K	0.05%	135
2018 Q3	$444K	Sell	26,741 -19,109	-42%	-$306K	0.05%	145
2018 Q2	$736K	Sell	45,850 -5,828	-11%	-$104K	0.65%	79
2018 Q1	$791K	Buy	51,678 +27,720	+116%	+$432K	0.69%	75
2017 Q4	$374K	Buy	+23,958	New	+$320K	0.47%	68

Virtus ETF Advisers's STML Position: Q2 2020 in Review

Virtus ETF Advisers sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 58,544 shares — an estimated $283K sold.

Virtus ETF Advisers first reported a position in STML in Q4 2017 and held it in 10 quarters. The position peaked at $875K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Virtus ETF Advisers reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Virtus ETF Advisers sold 58,544 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $283K.
Virtus ETF Advisers first reported a position in Stemline Therapeutics, Inc. in Q4 2017 and held it in 10 quarters.
Virtus ETF Advisers's Stemline Therapeutics, Inc. position peaked at $875K in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.